Kush Parmar | Managing Partner
5A.M. Ventures

Kush Parmar, Managing Partner, 5A.M. Ventures

Kush M Parmar, M.D., Ph.D. is a Managing Partner at 5AM Ventures and joined in 2010 from Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. Dr. Parmar serves as a Director on the Boards of Arvinas, Audentes (NASDAQ: BOLD), Homology and scPharmaceuticals.  He previously served as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J) and was Board Observer for Envoy (acquired by Takeda), Achaogen (NASDAQ: AKAO) and Pulmatrix (NASDAQ: PULM). Dr. Parmar serves on the Scientific Advisory Council of Princeton University’s Department of Molecular Biology and for the Grace Wilsey Foundation. He is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals. At Princeton University, Dr. Parmar worked on developmental genetics with Eric F. Wieschaus (Nobel Prize in Medicine in 1995). He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School. Dr. Parmar is based in the Boston, MA office.


World Orphan Drug Congress USA 2018 - Conference Day One @ 11:25

VC Panel: Investing in the orphan drug space – derisking commercial models and driving biotechs to successful launches

  • Assessing advanced therapies commercial opportunities – and risks – as the new frontier of investment in rare disease companies
  • Type of work and diligence to obtain comfort with the ultimate market opportunity
  • Assessing barriers to entry including therapeutic modality and IP
  • Regulators role in incentivizing or impeding the ability to develop products both domestically and abroad. What can be different?

back to speakers